Allscripts finalizes purchase of McKesson’s health IT business

Allscripts has closed its purchase of McKesson Corporation’s Enterprise Information Solutions (EIS), the hospital and health IT system business. The acquisition, which cost Allscripts $185 million, doubles Allscripts' client base in the United States.

By acquiring EIS, Allscripts will be able to invest in its current Paragon and Sunrise solutions. Paragon, the integrated electronic health record (EHR) and revenue management solution for small hospitals, and Sunrise, the platform used for larger and more complex health systems, will effectively double the amount of current EHR hospitals clients in the U.S. Additionally, current EIS customers will gain access to Allscripts’ population health management solution CareInMotion, Revenue Cycle Management Services, post-acute and precision medicine solutions.

“Our highest priority is to successfully meet our clients’ complex needs today and in the future,” said Allscripts CEO Paul M. Black. “It’s critical that healthcare organizations deliver the best care possible, and we expect this transaction will enable Allscripts to offer the most comprehensive, high-performing health information technology and solutions, which will help clinicians achieve our shared mission.”

“This strategic move by Allscripts represents its ongoing commitment to healthcare providers and their patients,” said John Bosco, Senior Vice President and CIO of Northwell Health. “As Allscripts continues its growth by expanding its reach to new hospitals and health systems, it’s also now positioned to better meet the needs of existing clients with the expansion of its portfolio of innovative solutions.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup